Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck’s Molnupiravir Open License With Medicines Patent Pool May Be Model

Executive Summary

Pharma industry critics herald the agreement for allowing many manufacturers around the world to make the COVID-19 therapeutic and for its transparency. If Merck can do it, they ask, why can’t other companies?

You may also be interested in...



MSD’s Asia Pacific Chief On Lagevrio’s Gains In Clinical Utility Amid Paxlovid Luster

David Peacock, President, Asia Pacific, MSD tells Scrip how Lagevrio has gained dominance in certain parts of the world, though Paxlovid may have received the ‘lion’s share’ of public attention.

Pharma’s Voluntary Licensing In India Successful In 2021 – But There Were Some Delicate Moments

Merck and Lilly tackle some early challenges before striking voluntary licensing deals for COVID-19 therapies with Indian firms. Data around the use of these drugs in low- and middle-income countries could also potentially make them ‘more acceptable’ elsewhere, experts say.

Wave Of Molnupiravir Generics In India Amid Early Physician Cheer

India authorizes molnupiravir for restricted emergency use in COVID-19, marking the arrival of around a dozen “affordable” generics of  Merck & Co. and Ridgeback Biotherapeutics' oral antiviral. Physicians say data are “pretty compelling” notwithstanding the narrow FDA nod.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145162

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel